![\"\"](\"https:\/\/medscriptum.org\/wp-content\/uploads\/2026\/06\/inhaler-ht-jt-260529_1780076318223_hpMain_4x3.jpg-e1780319547148-300x218.avif\")
Afrezza relies on a small, compact, handheld inhaler. Through it, powdered insulin is delivered into the lungs, where it is rapidly absorbed into the bloodstream. This delivery system, known as “Technosphere,” was designed to be used immediately before meals and takes effect instantly. Because the medication quickly reaches peak concentration and clears the body rapidly, it closely mimics the natural insulin spike that a healthy pancreas would produce in response to food.<\/p>\n
It is important to emphasize that inhaled insulin is strictly a mealtime medication. For children with type 1 diabetes, it cannot replace long-acting basal insulin, which they still require to stabilize background blood sugar levels throughout the day.<\/p>\n
What is the FDA’s Decision Based On?<\/strong><\/p>\n The regulatory body based its approval decision in part on the INHALE-1 clinical trial. The study enrolled 230 youth aged 4 to 17 with diabetes (the vast majority having type 1). Participants were randomly assigned to two groups: for 26 weeks, one group used inhaled insulin before meals, while the other used a rapid-acting injectable analog. Both groups continued their basal insulin therapy in parallel.<\/p>\n The results regarding blood glucose control were mixed. The average hemoglobin A1c (HbA1c) level\u2014which measures blood sugar over approximately three months\u2014was nearly identical in both groups at the start of the study. After 26 weeks, HbA1c levels rose slightly in the inhaled insulin group but remained stable in the injection group. While this difference was minimal, it failed to meet the pre-specified statistical threshold required to prove that the inhaled form is non-inferior (equally effective) to injections.<\/p>\n Providing objective information on this point is crucial. The study failed to prove that inhaled insulin manages blood sugar levels in pediatric patients exactly as effectively as traditional injection methods.<\/p>\n Nevertheless, the trial demonstrated a favorable safety profile\u2014no serious adverse events or significant declines in lung function were recorded during the observation period. Furthermore, children in the inhaled insulin group gained noticeably less weight, and overall treatment satisfaction scores were substantially higher.<\/p>\n For Whom Is the Medication Not Recommended?<\/strong><\/p>\n Inhaled insulin is not a suitable alternative for everyone. Individuals diagnosed with chronic lung diseases\u2014including asthma and chronic obstructive pulmonary disease (COPD)\u2014should not use this medication. These conditions can significantly alter the drug’s bioavailability and potentially worsen respiratory symptoms. Given the high prevalence of asthma in children, this poses a serious clinical limitation. Consequently, families will need to evaluate the appropriateness of this therapy thoroughly with their physicians.<\/p>\n Cost and Accessibility<\/strong><\/p>\n According to MannKind, eligible individuals will have access to Afrezza for $35 or less per month through its patient support program, MannKind Cares. Given the financial toxicity often associated with managing type 1 diabetes, this price cap represents a vital source of financial relief for families.<\/p>\n